Natural Development of Antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Protein Antigens during the First 13 Years of Life
- 1 November 2016
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 23 (11) , 878-883
Abstract
Conserved protein antigens have been investigated as vaccine candidates against respiratory pathogens. We evaluated the natural development of antibodies against Streptococcus pneumoniae , Haemophilus influenzae , and Moraxella catarrhalis proteins during childhood. Serum samples were collected from 50 healthy children from their first months to age 13 years (median sampling interval, 6 months). We also analyzed serum samples from 24 adults. Serum IgG antibodies against eight pneumococcal proteins (Ply, CbpA, PspA 1 and 2, PcpA, PhtD, StkP-C, and PcsB-N), three H. influenzae proteins, and five M. catarrhalis proteins were measured using a multiplexed bead-based immunoassay. Antibody levels were analyzed using multilevel mixed-effects regression and Spearman's correlation. Antibody levels against pneumococcal proteins peaked at 3 to 5 years of age and then reached a plateau. Antibody levels against H. influenzae proteins peaked during the second year and then stabilized. Antibody levels against M. catarrhalis proteins peaked during the first year and then slowly decreased. Peak antibody levels during childhood were higher than those of adults. Correlations among pneumococcal antibody levels were highest among anti-CbpA, anti-PcpA, and anti-PhtD antibodies ( r = 0.71 to 0.75; P < 0.001). The children presented 854 symptomatic respiratory infections on 586 occasions. Symptomatic respiratory infections did not improve prediction of antibody levels in the regression model. The maturation of immune responses against the investigated pneumococcal proteins shares similarities, especially among CbpA, PcpA, and PhtD. Antibody production against H. influenzae and M. catarrhalis proteins starts early in life and reaches peak levels earlier than antibody production against the pneumococcal proteins. Basal antibody levels are not related to the occurrence of symptomatic respiratory infections.Keywords
Funding Information
- Bahia State Agency for Research Funding
- Brazilian Council for Scientific and Technological Development
- National Institute for Health and Welfare
- Turku University Hospital Research Foundation
- Rauno and Anne Puolimatka Foundation
- Sohlberg Foundation
- Research Council of Finland
This publication has 33 references indexed in Scilit:
- Serological diagnosis of pneumococcal infection in children with pneumonia using protein antigens: A study of cut-offs with positive and negative controlsJournal of Immunological Methods, 2016
- Vaccine targets againstMoraxella catarrhalisExpert Opinion on Therapeutic Targets, 2015
- Synchrony in serum antibody response to conserved proteins ofStreptococcus pneumoniaein young childrenHuman Vaccines & Immunotherapeutics, 2015
- Early acquisition and high nasopharyngeal co-colonisation by Streptococcus pneumoniae and three respiratory pathogens amongst Gambian new-borns and infantsBMC Infectious Diseases, 2011
- Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimatesThe Lancet, 2009
- Development of natural antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A and pneumolysin in Filipino pregnant women and their infants in relation to pneumococcal carriageVaccine, 2006
- Dynamics of nasopharyngeal colonization by potential respiratory pathogensJournal of Antimicrobial Chemotherapy, 2002
- Nasopharyngeal Carriage ofStreptococcus pneumoniaein Finnish Children Younger Than 2 Years OldThe Journal of Infectious Diseases, 2001
- Natural Development of Antibodies to Pneumococcal Surface Protein A, Pneumococcal Surface Adhesin A, and Pneumolysin in Relation to Pneumococcal Carriage and Acute Otitis MediaThe Journal of Infectious Diseases, 2000
- Population‐based genetic screening for the estimation of Type 1 diabetes mellitus risk in Finland: selective genotyping of markers in the HLA‐DQB1, HLA‐DQA1 and HLA‐DRB1 lociDiabetic Medicine, 1999